<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Emapalumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Emapalumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Emapalumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="119704" href="/d/html/119704.html" rel="external">see "Emapalumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="119753" href="/d/html/119753.html" rel="external">see "Emapalumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52449948"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gamifant</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F52464625"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Monoclonal Antibody</span></li></ul></div>
<div class="block don drugH1Div" id="F53462706"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Tuberculosis screening should be completed prior to emapalumab therapy. Dose should be based on actual body weight.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5101dfc2-2f40-4c2e-b5e9-3367d3ad05b1">Primary hemophagocytic lymphohistiocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hemophagocytic lymphohistiocytosis (HLH):</b> IV: Initial dose: 1 mg/kg/dose twice weekly (ie, every 3 to 4 days); subsequent doses may be increased based on clinical and laboratory criteria. After the clinical condition is stabilized, decrease dose to the previous level to maintain clinical response. Continue until hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity; discontinue when therapy is no longer required for HLH.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose modification:</i> If inadequate response (see Criteria for dose increase), titrate dose as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3: May increase dose to 3 mg/kg/dose if meets criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 6 and beyond: May increase dose to 6 mg/kg/dose if meets criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 9 and beyond: May increase dose to 10 mg/kg/dose if (based on initial signs of response) assessment by health care provider indicates that a further increase in emapalumab dose may be of benefit.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Criteria for dose increase:</b> Inadequate response as determined by health care provider assessment and at least one of the following criteria:</p>
<p style="text-indent:-2em;margin-left:8em;">Fever (persistent or recurrent)</p>
<p style="text-indent:-2em;margin-left:8em;">Platelets: Baseline &lt;50,000/mm<sup>3</sup> without improvement to &gt;50,000/mm<sup>3</sup>
<b>or</b> baseline &gt;50,000/mm<sup>3</sup> and &lt;30% improvement, <b>or</b> baseline &gt;100,000/mm<sup>3</sup> and any decrease to &lt;100,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils: Baseline &lt;500/mm<sup>3</sup> without improvement &gt;500/mm<sup>3</sup>
<b>or</b> baseline &gt;500 to 1,000/mm<sup>3</sup> and decrease to &lt;500/mm<sup>3</sup>
<b>or</b> baseline 1,000 to 1,500/mm<sup>3</sup> and decrease to &lt;1,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Ferritin: Baseline ≥3,000 ng/mL and &lt;20% decrease <b>or</b> baseline &lt;3,000 ng/mL and any increase to &gt;3,000 ng/mL</p>
<p style="text-indent:-2em;margin-left:8em;">Splenomegaly (any worsening)</p>
<p style="text-indent:-2em;margin-left:8em;">Coagulopathy (both D-dimer and fibrinogen criteria must apply): D-Dimer: Abnormal at baseline and no improvement <b>AND</b> Fibrinogen: Baseline levels ≤100 mg/dL and no improvement <b>or</b> baseline levels &gt;100 mg/dL and any decrease to &lt;100 mg/dL</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedication and concomitant therapy:</b> Administer prophylaxis for herpes zoster, <i>Pneumocystis jirovecii</i>, and for fungal infections prior to emapalumab administration. Administer tuberculosis prophylaxis to patients at risk for tuberculosis or known to have a positive purified protein derivative (PPD) test result or a positive interferon gamma (IFNγ) release assay. If patient is not receiving baseline dexamethasone treatment (≥5 mg/m<sup>2</sup>/day), begin dexamethasone at a dose of at least 5 to 10 mg/m<sup>2</sup>/day beginning 1 day prior to initiation of emapalumab. For patients receiving baseline dexamethasone, continue the regular dexamethasone dose, as long as the dose is at least 5 mg/m<sup>2</sup>/day. Dexamethasone may be tapered according to clinical judgement.</p></div>
<div class="block dop drugH1Div" id="F52812471"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Tuberculosis screening should be completed prior to emapalumab therapy. Dose should be based on actual body weight.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5101dfc2-2f40-4c2e-b5e9-3367d3ad05b1">Primary hemophagocytic lymphohistiocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hemophagocytic lymphohistiocytosis (HLH):</b> Infants, Children, and Adolescents: IV: Initial dose: 1 mg/kg/dose twice weekly (ie, every 3 to 4 days); subsequent doses may be increased based on clinical and laboratory criteria. After the clinical condition is stabilized, decrease dose to the previous level to maintain clinical response. Continue until hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity; discontinue when therapy is no longer required for HLH.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose modification:</i> If inadequate response (see Criteria for dose increase), titrate dose as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3: May increase dose to 3 mg/kg/dose if meets criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 6 and beyond: May increase dose to 6 mg/kg/dose if meets criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 9 and beyond: May increase dose to 10 mg/kg/dose if (based on initial signs of response) assessment by health care provider indicates that a further increase in emapalumab dose may be of benefit.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Criteria for dose increase:</b> Inadequate response as determined by health care provider assessment and at least one of the following criteria:</p>
<p style="text-indent:-2em;margin-left:8em;">Fever (persistent or recurrent)</p>
<p style="text-indent:-2em;margin-left:8em;">Platelets: Baseline &lt;50,000/mm<sup>3</sup> without improvement to &gt;50,000/mm<sup>3</sup>
<b>or</b> baseline &gt;50,000/mm<sup>3</sup> and &lt;30% improvement, <b>or</b> baseline &gt;100,000/mm<sup>3</sup> and any decrease to &lt;100,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils: Baseline &lt;500/mm<sup>3</sup> without improvement &gt;500/mm<sup>3</sup>
<b>or</b> baseline &gt;500 to 1,000/mm<sup>3</sup> and decrease to &lt;500/mm<sup>3</sup>
<b>or</b> baseline 1,000 to 1,500/mm<sup>3</sup> and decrease to &lt;1,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Ferritin: Baseline ≥3,000 ng/mL and &lt;20% decrease <b>or</b> baseline &lt;3,000 ng/mL and any increase to &gt;3,000 ng/mL</p>
<p style="text-indent:-2em;margin-left:8em;">Splenomegaly (any worsening)</p>
<p style="text-indent:-2em;margin-left:8em;">Coagulopathy (both D-dimer and fibrinogen criteria must apply): D-Dimer: Abnormal at baseline and no improvement <b>AND</b> Fibrinogen: Baseline levels ≤100 mg/dL and no improvement <b>or</b> baseline levels &gt;100 mg/dL and any decrease to &lt;100 mg/dL</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedication and concomitant therapy:</b> Administer prophylaxis for herpes zoster, <i>Pneumocystis jirovecii</i>, and for fungal infections prior to emapalumab administration. Administer tuberculosis prophylaxis to patients at risk for tuberculosis or known to have a positive purified protein derivative (PPD) test result or a positive interferon gamma (IFNγ) release assay. If patient is not receiving baseline dexamethasone treatment (≥5 mg/m<sup>2</sup>/day), begin dexamethasone at a dose of at least 5 to 10 mg/m<sup>2</sup>/day beginning 1 day prior to initiation of emapalumab. For patients receiving baseline dexamethasone, continue the regular dexamethasone dose, as long as the dose is at least 5 mg/m<sup>2</sup>/day. Dexamethasone may be tapered according to clinical judgement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52464739"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provide in the manufacturer's labeling; however, renal impairment (including dialysis) had no clinically meaningful effect on emapalumab pharmacokinetics.</p></div>
<div class="block dohp drugH1Div" id="F52464740"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provide in the manufacturer's labeling; however, hepatic impairment had no clinically meaningful effect on emapalumab pharmacokinetics.</p></div>
<div class="block doa drugH1Div" id="F52422973"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="119704" href="/d/html/119704.html" rel="external">see "Emapalumab: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Test for tuberculosis (TB) infection (using purified protein derivative [PPD] or IFNγ release assay) and evaluate for TB risk factors prior to emapalumab treatment. Monitor for TB, adenovirus, Epstein-Barr virus, and cytomegalovirus every 2 weeks (and as clinically indicated) during emapalumab treatment. Premedication is recommended (see below). Dosing should be based on actual body weight.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5101dfc2-2f40-4c2e-b5e9-3367d3ad05b1">Primary hemophagocytic lymphohistiocytosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary hemophagocytic lymphohistiocytosis:</b> IV: Initial: 1 mg/kg twice a week (every 3 or 4 days); subsequent doses may be increased based on clinical and laboratory criteria. After the clinical condition is stabilized, decrease dose to the previous level to maintain clinical response. Continue until hematopoietic stem cell transplantation (HSCT) or unacceptable toxicity; discontinue when therapy is no longer required for hemophagocytic lymphohistiocytosis.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Dosage modification:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment day and dose: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Day 1 initial dose: 1 mg/kg</p>
<p style="text-indent:-2em;margin-left:6em;">Day 3: May increase to 3 mg/kg if meet criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 6 and beyond: Increase to 6 mg/kg if meet criteria for dose increase</p>
<p style="text-indent:-2em;margin-left:6em;">Day 9 and beyond: Increase to 10 mg/kg if (based on initial signs of response) assessment by health care provider indicates that a further increase in emapalumab dose may be of benefit</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Criteria for dose increase: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Unsatisfactory improvement in clinical condition (assessed by health care provider) AND at least one of the following:</p>
<p style="text-indent:-2em;margin-left:8em;">Fever (persistent or recurrent)</p>
<p style="text-indent:-2em;margin-left:8em;">Platelets: Baseline &lt;50,000/mm<sup>3</sup> without improvement to &gt;50,000/mm<sup>3</sup>
<b>or</b> baseline &gt;50,000/mm<sup>3</sup> and &lt;30% improvement, <b>or</b> baseline &gt;100,000/mm<sup>3</sup> and any decrease to &lt;100,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Neutrophils: Baseline &lt;500/mm<sup>3</sup> without improvement to &gt;500/mm<sup>3</sup>
<b>or</b> baseline &gt;500 to 1,000/mm<sup>3</sup> and decrease to &lt;500/mm<sup>3</sup>
<b>or</b> baseline 1,000 to 1,500/mm<sup>3</sup> and decrease to &lt;1,000/mm<sup>3</sup></p>
<p style="text-indent:-2em;margin-left:8em;">Ferritin: Baseline ≥3,000 ng/mL and &lt;20% decrease <b>or</b> baseline &lt;3,000 ng/mL and any increase to &gt;3,000 ng/mL.</p>
<p style="text-indent:-2em;margin-left:8em;">Splenomegaly (any worsening)</p>
<p style="text-indent:-2em;margin-left:8em;">Coagulopathy (both D-dimer and fibrinogen must apply): D-Dimer: Abnormal at baseline and no improvement; Fibrinogen: Baseline levels ≤100 mg/dL and no improvement <b>or</b> baseline levels &gt;100 mg/dL and any decrease to &lt;100 mg/dL.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premedication and concomitant therapy:</b> Administer prophylaxis for herpes zoster, <i>pneumocystis jirovecii</i>, and for fungal infections prior to emapalumab administration. Administer tuberculosis (TB) prophylaxis to patients at risk for TB, or known to have a positive PPD test result or a positive IFNγ release assay. For patients not receiving baseline dexamethasone treatment, begin dexamethasone at a dose of at least 5 to 10 mg/m<sup>2</sup>/day beginning 1 day prior to initiation of emapalumab. For patients receiving baseline dexamethasone, continue the regular dexamethasone dose, as long as the dose is at least 5 mg/m<sup>2</sup>/day. Dexamethasone may be tapered according to clinical judgement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F52422976"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal impairment (including dialysis) had no clinically meaningful effect on emapalumab pharmacokinetics.</p></div>
<div class="block doha drugH1Div" id="F52422977"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, mild, moderate, or severe hepatic impairment had no clinically meaningful effect on emapalumab pharmacokinetics.</p></div>
<div class="block adr drugH1Div" id="F52159111"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (41%), tachycardia (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Irritability (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Appendicitis (≤32%), constipation (15%), abdominal pain (12%), diarrhea (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytosis (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (56%), viral infection (32% to 41%), bacterial infection (35%), bacteremia (≤32%), histoplasmosis (≤32%), necrotizing fasciitis (≤32%), sepsis (≤32%), cytomegalovirus disease (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonia (≤32%), cough (12%), tachypnea (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (27%), fever (24%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (&lt;10%), peripheral edema (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gastrointestinal hemorrhage (&lt;10%), vomiting (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (&lt;10%), epistaxis (&lt;10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Multi-organ failure (≥3%)</p></div>
<div class="block coi drugH1Div" id="F52144242"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F52422961"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Infections may commonly occur. Emapalumab may increase the risk of fatal and serious infections including specific pathogens favored by IFNγ neutralization (mycobacteria, herpes zoster virus, and <i>Histoplasma capsulatum</i>); do not administer emapalumab to patients with infections caused by these pathogens until appropriate treatment has been initiated. Serious infections such as pneumonia, bacteremia, sepsis, disseminated histoplasmosis, necrotizing fasciitis, viral infections, and perforated appendicitis were observed in nearly one-third of patients receiving emapalumab in clinical trials. Reported infections were predominantly viral and bacterial, although fungal infections and infections with an unidentified pathogen also occurred. Prior to initiating emapalumab, evaluate for tuberculosis (TB) risk factors and test for TB infection (latent TB) by purified protein derivative (PPD) testing, polymerase chain reaction (PCR), or IFNγ release assay. Administer TB prophylaxis to patients at risk for TB or known to have a positive PPD test result. Prophylaxis for herpes zoster, <i>pneumocystis jirovecii, </i>and fungal infection should also be administered during emapalumab treatment. Utilize surveillance testing during treatment. Monitor closely for signs/symptoms of infection; promptly initiate a complete diagnostic workup appropriate for an immunocompromised patient and initiate appropriate antimicrobial therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion-related reactions (including drug eruption, pyrexia, rash, erythema, and hyperhidrosis) have been reported in over one-fourth of patients treated with emapalumab. Infusion-related reactions occurred during the first infusion in one-third of these patients. Infusion reactions were mild to moderate. Monitor for infusion-related reactions. If an infusion reaction occurs, interrupt infusion and manage appropriately, then continue with the infusion rate reduced.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Do not administer live or live attenuated vaccines to patients receiving emapalumab and for at least 4 weeks following the last emapalumab dose (safety of immunization with live vaccines during or following emapalumab has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F52449949"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gamifant: Emapalumab-lzsg 10 mg/2 mL (2 mL); Emapalumab-lzsg 50 mg/10 mL (10 mL); Emapalumab-lzsg 100 mg/20 mL (20 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F52449947"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52605669"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Gamifant Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $4,007.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $2,026.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/20 mL (per mL): $2,026.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614691"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: If diluted solution was refrigerated, allow solution to come to room temperature prior to administration. Do not shake. Administer over 1 hour through a 0.2-micron low protein-binding filter. Do not infuse with other medications. If an infusion reaction occurs, interrupt infusion and manage appropriately, then continue with the slower infusion rate.</p></div>
<div class="block adm drugH1Div" id="F52422980"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Infuse over 1 hour through an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 micron inline filter. Do not shake. Allow solution to reach room temperature prior to infusion. Do not infuse with other medications. If an infusion reaction occurs, interrupt infusion and manage appropriately, then continue with the infusion rate reduced.</p></div>
<div class="block sts drugH1Div" id="F52422963"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2ºC to 8ºC (36ºF to 46ºF); do not freeze. Store in original carton to protect from light. Do not shake. Solutions diluted for infusion should be used immediately after preparation; however, diluted solutions may be stored at 2ºC to 8ºC (36ºF to 46ºF) for a maximum of 4 hours from the time of dilution; do not freeze; allow diluted solution to reach room temperature prior to infusion.</p></div>
<div class="block usep drugH1Div" id="F53571515"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy (FDA approved in all ages)</p></div>
<div class="block mst drugH1Div" id="F52422956"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Emapalumab may be confused with avelumab, durvalumab, eculizumab, elotuzumab, emicizumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Gamifant may be confused with GamaSTAN.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52160948"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F52160945"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of immunosuppressive therapy is reduced. Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing therapeutic immunosuppressants several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Denosumab.  Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and immunosuppressants. If combined, monitor for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating immunosuppressants if possible. If vaccination occurs less than 2 weeks prior to or during therapy, revaccinate 2 to 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Pimecrolimus. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Therapeutic Immunosuppressant Agents).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Tofacitinib.  Management: Coadministration of tofacitinib with potent immunosuppressants is not recommended. Use with non-biologic disease-modifying antirheumatic drugs (DMARDs) was permitted in psoriatic arthritis clinical trials.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of immunosuppressants when possible. Patients vaccinated less than 14 days before initiating or during therapy should be revaccinated at least 2 to 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Vaccines (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Therapeutic Immunosuppressant Agents) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F52422959"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block mopp drugH1Div" id="F53571516"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for clinical improvement based on platelet counts, neutrophil counts, ferritin, D-dimer and fibrinogen, fever, and signs/symptoms of splenomegaly.</p>
<p style="text-indent:-2em;margin-left:2em;">Prior to initiating emapalumab, evaluate for tuberculosis risk factors and test for latent infection by purified protein derivative (PPD) testing, polymerase chain reaction (PCR), or interferon gamma (IFNγ) release assay. Monitor for tuberculosis, adenovirus, Epstein-Barr virus, and cytomegalovirus every 2 weeks (and as clinically indicated) during emapalumab treatment. Surveillance testing for herpes zoster, <i>Pneumocystis jirovecii, </i>and fungal infection should be utilized during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor closely for signs and symptoms of infection; promptly initiate a complete diagnostic workup appropriate for an immunocompromised patient. Monitor for infusion-related reactions.</p></div>
<div class="block pha drugH1Div" id="F52422966"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Emapalumab is an interferon gamma (IFNγ) blocking monoclonal antibody. IFNγ is hypersecreted in hemophagocytic lymphohistiocytosis (HLH); emapalumab binds to IFNγ and neutralizes it.</p></div>
<div class="block phk drugH1Div" id="F52422967"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d </sub>(based on a 70 kg patient): Central: 4.2 L; Peripheral: 5.6 L</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Emapalumab is likely degraded into small peptides and amino acids via catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Healthy subjects: ~22 days; Patients with hemophagocytic lymphohistiocytosis (HLH): 2.5 to 18.9 days</p></div>
<div class="block phksp drugH1Div" id="F52422971"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Body weight (2 to 82 kg) was a significant covariate of emapalumab pharmacokinetics (therefore supporting body weight-based dosing).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emapalumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control and Prevention (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emapalumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gamifant.1">
<a name="Gamifant.1"></a>Gamifant (emapalumab-lzsg) [prescribing information]. Waltham, MA: Sobi Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emapalumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emapalumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/emapalumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120129 Version 108.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
